Tesamorelin guide & protocols

Tesamorelin is unusual company on this site. Most growth hormone peptides circulate on convention and hope; this one has an approved product, a label, and a documented daily amount behind it. That makes the dosing section below easier to write and harder to argue with. Below is the daily pattern people actually run, how it's cycled and stacked, and why the arithmetic on this compound surprises people who priced it by the milligram.

Vial size isn't part of what follows, since the amount of bacteriostatic water you add sets your concentration either way. Our reconstitution calculator handles that math for whatever vial and target amount you're working with.

What it is

Tesamorelin is a synthetic version of growth hormone-releasing hormone, the signal your hypothalamus sends to tell the pituitary to release growth hormone. It's been modified at one end to survive longer in the body than the natural version does, which is what makes it usable at all.

The important part of how it works is what it doesn't do. It doesn't put growth hormone into you. It asks your own pituitary to make its own, in its own rhythm, which means the body's normal feedback loop stays intact and the release stays pulsatile rather than flat. That's the whole argument for this category over injected growth hormone itself, and tesamorelin is the member of it with the most evidence attached.

What people use it for

Visceral fat is the headline. Not fat generally, and not the fat you can pinch, but the deep abdominal fat that sits around the organs and behaves differently from the rest. That's what the approved product was approved to reduce, and it's what most people come looking for. It's a specific enough target that tesamorelin doesn't really compete with the GLP-1 compounds, it sits beside them.

Liver fat is the second thread, and it follows naturally from the first, since the same deep-abdominal pattern tends to travel with a fatty liver. Beyond that, people are interested in the general growth hormone effects, sleep quality, recovery, and how the body composition sits, which are the reasons anyone looks at this category at all. Interest in what raising growth hormone signalling does for memory and thinking exists too, and it's the least settled of the lot.

Formulations

Tesamorelin ships as a lyophilized powder for subcutaneous injection. Across the vendors we track, 10 mg vials dominate, with 5 mg and 20 mg as the common alternatives and a scattering of larger sizes. Note the gap between that and the pharmacy product, which comes in 1 mg and 2 mg vials sized to a single day. Research vendors sell it in multiples of a week instead.

One difference worth knowing: the approved product is reconstituted with sterile water and used immediately, one vial per dose. Research-grade material gets reconstituted with bacteriostatic water and drawn from repeatedly over days, which is a genuinely different handling situation and the reason the storage section below matters more here than on most pages.

Dosing protocols

Tesamorelin is one of the few compounds on this site whose central number comes from an approved product's own labelling rather than from circulating convention. What people run is either that amount directly or a reduction from it, and the patterns below say which is which.

See the Tesamorelin research notes for the trial background behind the numbers.

All patterns above are subcutaneous injection, commonly into abdominal fat.

Why this one costs more than it looks

Daily dosing changes the arithmetic completely, and this is the thing people get wrong when they price tesamorelin against a weekly compound. At 2 mg daily, a 10 mg vial is five days. Not five weeks. A full week runs 14 mg, and the 26-week stretch the approved studies ran works out to 364 mg (2 mg times 182 days). Even the reduced 1 mg pattern over twelve weeks is 84 mg. Compare vendors against a number like that rather than against the price of a single vial, because a cheap 10 mg vial that lasts five days is not cheap.

How much to reconstitute at once: the usual 28-day guidance for a reconstituted vial is close to irrelevant here, because at 2 mg daily nothing survives 28 days. A 10 mg vial is gone in five, so the whole vial gets reconstituted at once and the shelf-life question never really comes up. Working example: 10 mg into 2 mL of bacteriostatic water gives 5,000 mcg per mL, so a 2 mg dose is 2,000 divided by 5,000, times 100, which is 40 units on a standard U-100 insulin syringe, and the vial holds exactly five of them. See how much to reconstitute at once for the general math.

Cycling guidelines

The evidence-backed pattern isn't a cycle at all. The approved use is continuous daily dosing, and the studies measured their results at 26 weeks and again at a year with treatment never stopping. Where the effect was measured after stopping, the visceral fat came back, which is the clearest signal available that this is an ongoing commitment rather than a course you complete.

Community practice departs from that, usually on cost. Twelve-to-sixteen-week blocks with time off in between are commonly described, as is the five-on-two-off weekly pattern in the table above. Both are reasonable-sounding and neither has anything published behind it, so the honest framing is that people run shorter because a daily peptide is expensive, not because a break was shown to help.

Signs a course is commonly stopped or reconsidered:

• Swelling in the hands, ankles or feet, or a puffy feeling, which is the most consistently reported effect in this category
• Joint pain or stiffness, or numbness and tingling in the hands
• Blood sugar drifting upward, which is a known effect of raising growth hormone signalling and the reason this compound is watched closely in anyone with insulin resistance
• Injection site reactions that don't settle, which is a genuine consideration when you're injecting daily rather than weekly

Stacking

Most commonly paired stack: Tesamorelin with Ipamorelin.

Rationale: the two push the pituitary through different doors. Tesamorelin acts on the growth hormone-releasing hormone receptor, Ipamorelin acts on the ghrelin receptor, and the argument is that using both produces a bigger release than either alone rather than just more of the same signal.

Protocol as run: both dosed once daily before sleep, on an empty stomach, as two separate injections. The timing convention is the load-bearing part of this stack, since both are meant to land alongside the body's own overnight release rather than compete with a meal.

Lighter stacks: CJC-1295 comes up constantly here, and it's worth being clear that it's a substitute rather than an addition, since it works on the same receptor tesamorelin does. Running both is doubling one signal, not combining two. BPC-157 shows up as a general recovery pairing with no growth hormone rationale behind it.

Combinations to approach carefully: anything that also raises blood sugar. Growth hormone signalling nudges insulin resistance upward on its own, and that's the effect the approved product's labelling watches most closely, so stacking tesamorelin with another compound pulling the same direction is the combination where the caution is real rather than theoretical.

Expected results timeline

Early weeks: sleep quality is what people report first, usually within the first week or two, and it's the most consistent early report in this whole category. Nothing visible is happening yet.

Months in: body composition changes are measured in months, not weeks. The studies took their primary measurements at 26 weeks, which is half a year of daily injections, and that's the honest timeline for the effect this compound is actually known for.

Extended, continued use: the results held at a year with continued dosing. They did not hold after stopping.

What to expect realistically: the visceral fat reduction reported in the approved studies was in the range of 15 to 18% against placebo, in a specific population with a specific fat-distribution problem. That number is measured on a scan, not on a scale or in a mirror, and deep abdominal fat is a small enough share of total body weight that a meaningful reduction in it may not move the number you weigh very much at all. People expecting a GLP-1-shaped result from this are usually disappointed, and they're measuring the wrong thing.

Administration technique

1. The lyophilized powder is reconstituted with bacteriostatic water, at a concentration set by the reconstitution calculator for the target daily amount.
2. The solution is swirled gently to dissolve rather than shaken, since agitation can degrade the peptide.
3. The calculated volume is drawn into an insulin syringe or similar fine-gauge syringe.
4. A subcutaneous site in the abdomen is chosen, which is the route used in the approved studies, with sites rotated daily so no spot is used twice in a row.
5. The skin is pinched and the injection given at roughly a 45-degree angle, held for a few seconds before withdrawal.
6. The dose is commonly given at night on an empty stomach, since food raises insulin and insulin blunts the growth hormone release this compound is trying to produce.
7. Daily injection makes site rotation a real discipline rather than an afterthought, so the site is commonly logged alongside the date.

Side effects and safety

Common: injection site reactions lead, which is unsurprising given the daily schedule. Joint pain, muscle aches, and swelling in the hands and feet follow, and all three are the classic signature of raised growth hormone signalling rather than anything specific to this compound.

Less common: carpal tunnel symptoms, numbness and tingling in the hands, and a rise in blood sugar. That last one is the effect worth watching most, since the approved product's labelling flags it and it is the plausible mechanism by which this compound could do harm in someone already sliding toward insulin resistance.

What we don't know: the studies were run in a specific population, adults with HIV who had developed a particular pattern of fat redistribution. Whether the same effect size holds in a healthy woman in her fifties looking at visceral fat for entirely different reasons has not been tested at anything like the same scale, and it's a real gap rather than a technicality. The approved product also carries a caution around anyone with active cancer, on the reasoning that raising growth hormone signalling could in principle accelerate cell growth, which has not been shown to happen but has not been ruled out either.

Contraindications: active cancer, pregnancy, and breastfeeding are the ones consistently carried over from the approved labelling. Diabetes and prediabetes aren't a flat contraindication but are the situation where the blood sugar effect stops being theoretical.

Drug interactions: anything affecting blood sugar control, including insulin and oral diabetes medications, since this compound pushes in the opposite direction. Corticosteroids interact with growth hormone signalling in both directions and are worth knowing about.

Tesamorelin vs. CJC-1295

CJC-1295 is the compound tesamorelin actually gets cross-shopped against. Both are versions of the same hypothalamic signal, both ask the pituitary to do the work, and the choice between them comes down almost entirely to how much evidence you want behind it against how much you want to spend and how often you want to inject.

Choose tesamorelin if: you want the one compound in this category with an approved product and a documented effect on the specific thing you're targeting, and the daily schedule and the cost are acceptable to you.

Choose CJC-1295 if: weekly dosing and a much lower running cost matter more than depth of evidence, and general growth hormone support rather than visceral fat specifically is what you're after.

See the CJC-1295 research notes for its own background, mechanism, and pricing.

Storage and handling

Lyophilized powder: refrigerate at 2 to 8°C and protect from light. The approved product's labelling says not to freeze it, which is a departure from the general freezer advice on this site and worth respecting for this compound specifically. Take lot-specific stability from the vendor's certificate of analysis.

Reconstituted solution: refrigerate. The usual 28-day window applies in principle but rarely binds in practice, since a daily schedule empties a vial well inside it. The approved product is reconstituted and used immediately, one vial per dose, so there's no manufacturer in-use window to borrow for a vial you're drawing from for a week. Avoid repeated freeze-thaw cycles.

Signs of degradation:

• Cloudiness or visible particles in a solution that was previously clear
• Discoloration of the powder or the reconstituted liquid
• Powder that has clumped or gone sticky, which usually means moisture reached it

FAQ

Is this the same as Egrifta? The molecule is. The manufacturing standard is not, and research-grade material isn't made or tested to pharmaceutical requirements.

How much do people run? 2 mg once daily is the approved amount and the anchor everything else sits below; 1 to 2 mg daily is what circulates for research-grade material.

Why at night? The convention lines the dose up with the body's own overnight growth hormone release, and food raises insulin, which blunts that release. It's convention rather than something the studies established.

How long before anything happens? Sleep changes are commonly reported in the first week or two. The body composition effect this compound is actually known for was measured at 26 weeks.

Will it help with regular weight loss? It targets deep abdominal fat specifically, which is a small share of total body weight, so it can work as intended and barely move the scale. That's not the compound failing, it's the wrong measurement.

Tesamorelin or CJC-1295? Tesamorelin for evidence and a documented visceral fat effect. CJC-1295 for weekly dosing and much lower cost.

Does it affect blood sugar? It can push it upward, and that's the effect the approved labelling watches most closely. It matters most for anyone already managing insulin resistance.

How is it stored? Refrigerated and out of the light, not frozen. A daily schedule empties a vial faster than the reconstituted shelf life is likely to matter.

Bottom line

Key dosing takeaways:

• 2 mg once daily is the anchor, and it comes from an approved product's own labelling rather than from circulating convention, which is rare on this site
• Daily dosing is the whole cost story: 14 mg a week, and 364 mg across the 26 weeks the approved studies ran
• The lower 1 mg pattern and the five-on-two-off pattern are both cost decisions, not refinements, and nothing published supports them as equivalent

Best practices:

• Price this against total milligrams over months, not against a vial, since a 10 mg vial is five days at the approved amount
• Rotating injection sites matters more here than on a weekly compound, and is worth logging alongside the date
• Watching blood sugar is the one monitoring step that isn't optional, particularly for anyone already close to the line

Works best for people who:

• Are specifically targeting deep abdominal fat rather than weight generally
• Want the growth hormone compound with real published evidence behind it and will pay for that
• Can commit to a daily injection over months rather than a weekly one

Tesamorelin is sold for research, and the studies behind it were run in a specific population that may not resemble you. You already know that. You're an adult making an informed call about your own body, and that's yours to make.